SYNAPTOGENIX, INC.
Newark, NJ · Biotech · Public
Bryostatin-1, a protein kinase C epsilon activator molecule for Alzheimer's disease treatment
- Grants
- $4.5M
- 2 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 23
- 2 granted · 21 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Long-term therapeutic effects of synthetic bryostatin-1 in advanced AD without memantine | $2,719,310 | |
| Federal grant | Department of Health and Human Services · Phase II · Long-term therapeutic effects of synthetic bryostatin-1 in advanced AD without memantine | $1,732,392 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1529 | PGI HOLDING CORPORATION | — | — |
| 1530 | EUNOIA BIO TECH, LLC | — | — |
| 1531 | Juno Therapeutics, Inc. | — | $1.0B |
| 1532 | SYNAPTOGENIX, INC. | — | — |
| 1533 | Akeso | — | — |
| 1534 | Ctrl Therapeutics | — | — |
| 1535 | Human Immunology Biosciences | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Treatment Of Amyotrophic Lateral Sclerosis Using Pkc Activatorsapplication
- Methods For Repairing Nerve Damage Using Pkc Activating Therapeutic Agentsapplication
- Methods Of Treating And Preventing Neurodegenerative Diseases With Hgf Activating Compoundsapplication
- Halogenated Esters Of Cyclopropanated Unsaturated Fatty Acids For Use In The Treatment Of Neurodegenerative Diseasesgranted
- Treatment Of Multiple Sclerosis Using Pkc Activatorsapplication
- Treatment Of Optic Nerve Inflammation Using Pkc Activatorsapplication
- Pkc-activating Compounds For The Treatment Of Neurodegenerative Diseasesapplication
- Pkc-activating Compounds For The Treatment Of Neurodegenerative Diseasesgranted
- Method Of Inducing Synaptogenesis By Administering Angiotensin And Analogues Thereofapplication
- Treatment Of Amyotrophic Lateral Sclerosis Using Pkc Activatorsapplication
- Methods Of Treating And Preventing Neurodegenerative Diseases With Hgf Activating Compoundsapplication
- Methods And Compositions For Treatment Of Alzheimer's Disease And Other Neurodegenerative Disordersapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.